Skip to main
  1. Stocks
  2. Coherus BioSciences
  3. Forecast
CHRS

Coherus BioSciences (CHRS) Stock Forecast & Price Target

Coherus BioSciences (CHRS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coherus Oncology is a compelling oncology story because it combines an approved, in-house PD-1 backbone with a differentiated pipeline that can create both near-term cash flow and long-term growth. Loqtorzi generated $14.0M in 3Q26 net product revenue, up 25% YoY, while management said quarterly burn should fall by $6M-$7M over the next two quarters after a ~30% headcount reduction and that $83.6M of cash provides runway through key clinical updates in 2026 and 2027. Fundamentally, the outlook is supported by promising esophageal cancer data for tagmokitug, competitive HCC signals for casdozokitug, and the possibility that pipeline success could expand Loqtorzi beyond NPC into a broader commercial franchise.

Bears say

Coherus Oncology is viewed negatively because its clinical evidence remains preliminary, with the 2L ESCC cohort showing only a 16.7% confirmed ORR at 700 mg, a 33.3% CBR, and no clear proof of PD-1 rescue in the only PD-1-pretreated patient. The bear case assumes casdozokitug and tagmokitug both fail in ESCC, which would leave only NPC Loqtorzi sales of about $240M in FY35, underscoring how much value depends on unproven pipeline assets rather than a broad commercial base. Additional downside comes from regulatory, competitive, and dilution risk, since approvals remain uncertain, rivals are entrenched, and the company may need more capital, with the latest per-share estimate already reflecting only about $9.8M in net cash across roughly 258.4M diluted shares.

Coherus BioSciences (CHRS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coherus BioSciences and is not a guaranteed prediction by Public.com or investment advice.

Coherus BioSciences (CHRS) Analyst Forecast & Price Prediction

Get the latest Coherus BioSciences (CHRS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Coherus BioSciences (CHRS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coherus BioSciences (CHRS) Forecast

Analysts have given Coherus BioSciences (CHRS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Coherus BioSciences (CHRS) has a Strong Buy consensus rating as of Nov 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coherus BioSciences (CHRS)


Coherus BioSciences (CHRS) Analyst Forecast & Price Prediction

Get the latest Coherus BioSciences (CHRS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Coherus BioSciences (CHRS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CHRS stock data and trends